Aplastic Anemia - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 81 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Aplastic Anemia - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Aplastic Anemia - Pipeline Review, H1 2016', provides an overview of the Aplastic Anemia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Aplastic Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Aplastic Anemia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Aplastic Anemia
- The report reviews pipeline therapeutics for Aplastic Anemia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Aplastic Anemia therapeutics and enlists all their major and minor projects
- The report assesses Aplastic Anemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Aplastic Anemia


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Aplastic Anemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Aplastic Anemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Aplastic Anemia Overview 7
Therapeutics Development 8
Pipeline Products for Aplastic Anemia - Overview 8
Aplastic Anemia - Therapeutics under Development by Companies 9
Aplastic Anemia - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Aplastic Anemia - Products under Development by Companies 12
Aplastic Anemia - Companies Involved in Therapeutics Development 13
3SBio Inc. 13
Acceleron Pharma, Inc. 14
Amgen Inc. 15
BioLineRx, Ltd. 16
F. Hoffmann-La Roche Ltd. 17
Novartis AG 18
Pluristem Therapeutics Inc. 19
Regen BioPharma, Inc. 20
Aplastic Anemia - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
Anemir - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
BL-8040 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Cell Therapy for Aplastic Anemia - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
eltrombopag olamine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Gene Therapy to Activate Telomerase for Aplastic Anemia - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
HemaXellerate - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
PLXR-18 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
romiplostim - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
sotatercept - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
thrombopoietin - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Aplastic Anemia - Recent Pipeline Updates 48
Aplastic Anemia - Dormant Projects 71
Aplastic Anemia - Discontinued Products 72
Aplastic Anemia - Product Development Milestones 73
Featured News & Press Releases 73
May 11, 2016: Regen BioPharma Discusses Recent Developments in Aplastic Anemia Therapy and Future Potential Expansion of HemaXellerate 73
Jan 26, 2016: Regen BioPharma Submits Application to FDA for Orphan Drug Designation for its HemaXellerate Product 73
Dec 15, 2015: Regen BioPharma Receives FDA Clearance to Initiate Clinical Trial of HemaXellerate 74
Nov 23, 2015: BioLineRx Announces Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions 75
Nov 17, 2015: Regen BioPharma Submits Response to FDA Questions on HemaXellerate Investigational New Drug Application 76
Nov 17, 2015: Pluristem to Present New Data on PLX-R18 at American Society of Hematology's Annual Meeting 76
Sep 25, 2015: Regen BioPharma Announces Positive Results from GLP Safety Study for HemaXellerate 77
Sep 10, 2015: BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Treatment for Hypoplastic Myelodysplastic Syndrome and Aplastic Anemia 77
Sep 02, 2015: Novartis receives EU approval for new Revolade use as first-in-class therapy for patients with severe aplastic anemia 78
Jul 24, 2015: Novartis drug Revolade recommended by CHMP for EU approval to treat patients with severe aplastic anemia, a serious blood disorder 79
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 80
Disclaimer 81

List of Tables

Number of Products under Development for Aplastic Anemia, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Aplastic Anemia - Pipeline by 3SBio Inc., H1 2016 13
Aplastic Anemia - Pipeline by Acceleron Pharma, Inc., H1 2016 14
Aplastic Anemia - Pipeline by Amgen Inc., H1 2016 15
Aplastic Anemia - Pipeline by BioLineRx, Ltd., H1 2016 16
Aplastic Anemia - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 17
Aplastic Anemia - Pipeline by Novartis AG, H1 2016 18
Aplastic Anemia - Pipeline by Pluristem Therapeutics Inc., H1 2016 19
Aplastic Anemia - Pipeline by Regen BioPharma, Inc., H1 2016 20
Assessment by Monotherapy Products, H1 2016 21
Number of Products by Stage and Target, H1 2016 23
Number of Products by Stage and Mechanism of Action, H1 2016 25
Number of Products by Stage and Route of Administration, H1 2016 27
Number of Products by Stage and Molecule Type, H1 2016 29
Aplastic Anemia Therapeutics - Recent Pipeline Updates, H1 2016 48
Aplastic Anemia - Dormant Projects, H1 2016 71
Aplastic Anemia - Discontinued Products, H1 2016 72